Drug Profile


Alternative Names: SSR 591813

Latest Information Update: 27 Feb 2008

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator sanofi-aventis
  • Class Azepines; Heterocyclic compounds with 4 or more rings; Small molecules; Smoking cessation therapies
  • Mechanism of Action Nicotinic receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued CNS disorders; Smoking withdrawal

Most Recent Events

  • 01 Oct 2007 Phase III development is ongoing
  • 30 Mar 2006 Phase-III clinical trials in Smoking withdrawal in European Union (PO)
  • 31 Aug 2005 Data from a media release have been added to the Drug Withdrawal therapeutic trials section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top